文献速递贫血与红细胞疾病

新型血浆血红素检测揭示β-地中海贫血与镰状细胞贫血疾病严重程度

A Novel Plasma Heme Assay Reveals Disease Severity in Beta-Thalassemia and Sickle Cell Anemia.
PubMed 文献 · Am J Hematol · 2026-04-22

本研究开发了一种新型血浆血红素光谱检测法,可定量血浆中血红蛋白、高铁血红蛋白、血红素和血红素结合蛋白。在镰状细胞病(SCD)和β-地中海贫血中,SCD血管内溶血更严重(血浆血红蛋白6.20 vs 2.52 μM,p<0.001),β-地中海贫血血浆血红素更高(11.00 vs 1.51 μM,p<0.0001)。β-地中海贫血中血浆血红素超过血红素结合蛋白清除能力的比例为72%,SCD为36%。

要点

  • 新型血浆血红素检测可区分血管内溶血程度,SCD血浆血红蛋白高于β-地中海贫血。
  • β-地中海贫血血浆血红素显著升高,反映无效造血与溶血混合来源。
  • β-地中海贫血中血浆血红素超过清除能力的比例高于SCD(72% vs 36%)。

核心结论

  • 新型血浆血红素检测可揭示β-地中海贫血和SCD的溶血部位与疾病严重程度。
  • SCD以血管内溶血为主,β-地中海贫血血浆血红素升高更显著且与临床严重程度相关。

研究设计与样本

  • 研究采用新型光谱法检测血浆中所有血红素相关物种,包括血红蛋白、高铁血红蛋白、血红素和血红素结合蛋白。

主要发现

  • SCD患者血浆血红蛋白为6.20 μM,β-地中海贫血为2.52 μM(p<0.001),个体间变异显著。
  • β-地中海贫血患者血浆血红素为11.00 μM,SCD为1.51 μM(p<0.0001)。
  • 所有患者血浆血红素结合蛋白与血浆血红素呈负相关。
  • 血浆血红素超过血红素结合蛋白清除能力的比例在β-地中海贫血为72%,SCD为36%。
  • β-地中海贫血中输血依赖患者血浆血红素显著高于非输血依赖患者;SCD中过量血红素升高与死亡风险显著增加相关。

临床怎么用

  • 该检测可用于评估溶血部位和疾病严重程度,辅助β-地中海贫血和SCD患者管理。
  • 在SCD中过量血红素可能作为死亡风险的新型生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anemia results from imbalanced hemoglobin or red blood cell production and clearance. Hemolytic anemia, caused by premature red blood cell removal, can be intravascular (in blood) or extravascular (erythrophagocytosis). Hemolysis is common in Sickle Cell Disease (SCD) and Beta-Thalassemia anemia (β-thalassemia), the most prevalent inherited hemolytic anemias. Hemolysis severity is primarily assessed by measuring indirect serum biomarkers such as lactate dehydrogenase, released by cytolysis, bilirubin and haptoglobin. However, these markers do not directly indicate either the cause or the primary site of hemolysis. We introduced a novel plasma heme assay that quantifies all heme-related species in plasma, including hemoglobin, methemoglobin, heme, and hemopexin. Our findings revealed a more profound intravascular red blood cell destruction in SCD compared to β-thalassemia as demonstrated by higher values of plasma hemoglobin, respectively 6.20 and 2.52 μM (p < 0.001), with significant inter-individual variability. In contrast, β-thalassemia patients exhibited higher plasma heme values (11.00 μM vs. 1.51 μM; p < 0.0001) reflecting a probable mixed origin (dyserythropoiesis and hemolysis). Plasma hemopexin was negatively correlated with plasma heme in all patients. Plasma heme exceeded hemopexin scavenging capability in 72% of β-thalassemia and 36% of SCD patients. In β-thalassemia, plasma heme levels were significantly higher in transfusion-dependent compared to non-transfusion-dependent patients, indicating that excess heme reflects clinical severity. In SCD, elevated concentration of excess heme was associated with a significant increased risk of mortality compared to LDH or reticulocytes%. This novel spectral assay offered significant benefits for diagnosis, treatment, and patient management.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kiger L, Hebert N, Bencheikh L, et al. A Novel Plasma Heme Assay Reveals Disease Severity in Beta-Thalassemia and Sickle Cell Anemia. Am J Hematol. 2026. PMID: 42020947. doi:10.1002/ajh.70314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。